Cabaletta Bio’s treatment of systemic sclerosis was granted orphan designation by the FDA, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CABA:
